Johnson & Johnson's Q4 earnings call highlighted a successful year with record sales, despite facing significant challenges such as market declines for drug-eluting stents and erythropoietin stimulating agents. The company's diversified portfolio and robust pipeline position it well for future growth. Management's guidance for 2008 suggests a positive outlook, with expected sales growth of 4-5% and EPS growth of $4.39-4.44. The company's focus on emerging markets, convergence of healthcare products and services, and development of leadership and talent also bode well for long-term success. Overall, the call suggests a stable and growing company with a strong foundation for future performance.

[1]